MIRA Prescription drugs, Inc. MIRA inventory is buying and selling larger on Monday after the corporate launched new preclinical findings from Ketamir-2, a novel oral ketamine analog.
The brand new preclinical information present that Ketamir-2 is 60% more practical than the FDA-approved neuropathic ache remedy gabapentin in lowering chemotherapy-induced ache.
The research used the paclitaxel (PTX) mannequin, wherein a standard chemotherapy drug, PTX, was administered to mice to induce neuropathic ache.
Additionally Learn: MIRA Prescription drugs’ Oral Ketamine Analog Achieves Full Normalization Of Neuropathic Ache In Animal Research
Whereas efficient in treating most cancers, PTX typically causes nerve injury, resulting in chemotherapy-induced neuropathy characterised by ache, numbness, and tingling.
To evaluate Ketamir-2’s efficacy, mice obtained PTX each different day for 4 doses, and ache sensitivity was measured utilizing the Von Frey filament (VFF) check.
On Day 9, on the optimum dose of 300 mg/kg, Ketamir-2 led to near-complete normalization of ache sensitivity, outperforming FDA-approved gabapentin by 60%, which supplied solely reasonable aid.
The corporate will current these findings and information from earlier research on the upcoming Ache Therapeutics Summit.
The corporate is making ready to submit an Investigational New Drug (IND) software by the top of 2024, with plans to start Section I scientific trials within the first quarter of 2025.
To maximise the event timeline, MIRA is contemplating conducting a number of Section 2 trials in parallel, particularly concentrating on neuropathic ache throughout totally different affected person populations, which might additional speed up Ketamir-2’s path to market.
Along with the continuing research, MIRA is within the technique of submitting a number of scientific journal publications that element Ketamir-2’s mechanism of motion, in addition to the outcomes from its ache and melancholy research.
Moreover, Ketamir-2 is below analysis for post-traumatic stress dysfunction (PTSD), with preclinical research at the moment underway.
MIRA is actively searching for authorities grants to help analysis on PTSD and different indications.
Worth Motion: MIRA inventory is up 40.30% at $1.81 on the final examine on Monday.
Learn Subsequent:
Market Information and Knowledge delivered to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
